Navigation Links
J.P. McCarthy Fund Grants $250,000 to Karmanos Cancer Institute
Date:7/30/2008

Increasing the Awareness and Capacity of Life-Saving Cord Blood

DETROIT, July 30 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Cancer Institute announced that it received a $250,000 multi-year grant from the J.P. McCarthy Fund of the Community Foundation for Southeast Michigan to benefit its J.P. McCarthy Cord Stem Cell Bank. The grant, which will be given in $50,000 increments over five years, will help enhance the collection area and expand the capacity to help people in need of cord stem cell transplants - non-embryonic stem cells that are extracted from the umbilical cord and placenta following the birth of a child.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO)

The J.P. McCarthy Cord Stem Cell Bank at the Karmanos Cancer Institute is one of two public cord blood banks in Michigan and the only center in the state with the National Marrow Donor program registry designation that requires compliance with the highest standards in cord blood banking.

"When my husband was diagnosed with Myelodyoplastic Syndrome (MDS) in 1995, the disease that took his life, there was a very limited bone marrow donor base and limited resources to help MDS patients and their families," said Judy McCarthy.

"The J.P. McCarthy Fund is committed to help educate the public and improve research to the cause and treatment of MDS, as well as expand the bone marrow and stem cell donor base. We commend the Karmanos Cancer Institute for its quality work in banking cord blood," added McCarthy.

According to the National Marrow Donor program, on any given day, there are more than 6,000 men, women and children in search of a life-saving donor match. Diseases such as leukemia, lymphoma, sickle-cell and other life-threatening diseases can be treated by bone marrow or cord blood transplant. Although many try to find a
'/>"/>

SOURCE Karmanos Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Jenny McCarthy Featured at National Autism Conference in Atlanta, November 9
2. Video Feed: Jenny McCarthy Honored at LEGOLAND(R) Californias Tree Lighting Ceremony Dedicated to Autism Awareness
3. TV Personality and Best-Selling Author Jenny McCarthy Comes to Detroit to Share Her Story of the Struggles and Triumphs of Raising Her Son, Evan, During a Day-Long Autism Workshop
4. Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board
5. Jenny McCarthy & Jim Carrey Host the Historic Green Our Vaccines March and Rally in Washington DC on June 4, 2008
6. Global Health Trax Joins Fight Against Autism With Jenny McCarthy and Generation Rescue
7. U.S. Labor Department Awards $10.1 Million for Safety and Health Training Grants
8. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
9. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
10. USAID Announces First Malaria Communities Program Grants
11. The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... ,, NEW YORK, Dec. 14 /PRNewswire-USNewswire/ -- ... (MTF) -- the largest survey on teen drug abuse ... underscores that teens, intentional abuse of prescription (Rx) and ... concern, with an alarming number of young people abusing ... Teen Abuse of Medication Continues to Be ...
(Date:12/14/2009)... SANTA ANA, Calif., Dec. 14 Grubb & Ellis ... directors has authorized a daily distribution to stockholders of record ... the period commencing on Jan. 1, 2010 and ending on ... on 365 days in the calendar year and will be ... a purchase price of $10.00 per share. These distributions ...
(Date:12/14/2009)... On December 9, 2009, the United States ... position that private insurance companies are "plans" and therefore ... other federal courts have held that contracts issued by ... Title 18 Section 1347, US vs. Frost ... been held to be a "plan," because, as the ...
(Date:12/14/2009)... hadn,t spread, study finds , , MONDAY, Dec. 14 (HealthDay ... death in male colon cancer survivors, researchers report. , ... men who,d been treated for stage I, stage II ... (nonmetastatic cancer). Every two years, the men were sent ... disease diagnoses, as well as their physical activity. A ...
(Date:12/14/2009)... shouldn,t worry most users, researcher says , , MONDAY, Dec. ... may have a small but statistically significant increased risk ... the medications, a new study finds. , "But statistical ... Jordan W. Smoller, an associate professor of psychiatry at ... in the Dec. 14 issue of Archives of ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3
... New Study in the Journal of Cosmetic Dermatology Finds Over-the-Counter ... for Helping to Clear Up Mild to Moderate EczemaEDISON, N.J., ... looking for a cost-effective way to control and heal this ... to consider. A new study in the March 2009 issue ...
... Surge in anxiety-linked hormone worsens blood sugar level, researchers suggest ... a key role in the development of type 2 diabetes ... has been given to the role of obesity in the ... important in this at-risk population," study co-author Anastasia Georgiades, of ...
... Inc. (NYSE: MED ) announced today that it ... for the period ended December 31, 2008 on Thursday, March ... Company will hold a conference call and web cast to ... a.m. ET.Interested parties can access the call by dialing (877) ...
... Minn., March 5 People across the country are now ... from Upsher-Smith Laboratories, Inc. AmLactin(R) Foot Cream Therapy provides ... dry and chapped feet because of its high concentration of ... Dry, chapped feet are the result of various factors ...
... Susan Dell Foundation awards grant totaling more than $3 ... -AUSTIN, Texas, March 5 The Michael & Susan ... The University of Texas School of Public ... expansion of the Coordinated Approach To Child Health (CATCH) ...
... Approvals for Intravenous Formulation of Temozolomide As Well As ... 5 Schering-Plough Corporation (NYSE: SGP ) ... FDA both approved the intravenous (IV) formulation of temozolomide ... of the drug. Temozolomide is marketed as TEMODAL(R) ...
Other Medicine News:Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 2Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 3Health News:Stress May Raise Diabetes Risk for Obese Black Women 2Health News:Medifast, Inc. to Announce Fourth Quarter and Fiscal Year 2008 Financial Results on Thursday, March 12, 2009 2Health News:New AmLactin(R) Foot Cream Immerses Feet in Moisture 2Health News:UT School of Public Health Program to Prevent Childhood Obesity Expands to Central Texas Middle Schools 2Health News:UT School of Public Health Program to Prevent Childhood Obesity Expands to Central Texas Middle Schools 3Health News:UT School of Public Health Program to Prevent Childhood Obesity Expands to Central Texas Middle Schools 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7
(Date:12/14/2009)... -- Travelers of Interstate 70 west of Indianapolis will ... more colorful when 10 multicolored art forms are installed ... going home , will eventually include 34 total pieces ... at Herron School of Art and Design, through the ... ,, Eli Lilly and Company (NYSE: LLY ...
(Date:12/14/2009)... Pa., Dec. 14 CPG International, ... engineered building products, introduces VYCOM, a rebranded ... the previous VYCOM Corporation and Scranton Products ... wholly recognized business unit within CPG International, ... Products Commercial. The VYCOM business unit has ...
(Date:12/14/2009)... Pharmaceutical Inc. (OTC Bulletin Board: OHRP) announced today ... in Irvine, CA, with offices also in New ... relations and corporate communications. Ohr Pharmaceutical is ... advanced drugs for underserved therapeutic needs. The Company ... markets: OHR/AVR118 for the treatment of Cachexia and ...
Breaking Medicine Technology:Public Art to Complete Transformation of Key Gateway into Indianapolis 2Public Art to Complete Transformation of Key Gateway into Indianapolis 3Public Art to Complete Transformation of Key Gateway into Indianapolis 4Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 2Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications 3Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 1Milwaukee Employers See Cost Savings with High Performance Provider Network 61921 2Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 1Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 2Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 3Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 4Four Senior Executives Join Orexigen 28R 29 Therapeutics Management Team 61916 5Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 1Pearl Therapeutics Appoints Howie Rosen to Board of Directors 14939 2
... and REBETOL(R) will be the only available hepatitis C therapy, approved ... ... approval, KENILWORTH, ... that the Committee for Medicinal,Products for Human Use (CHMP) of the ...
... Sept. 24 Knopp Neurosciences Inc. ("Knopp"),today ... clinical trial of KNS-760704, a,small molecule therapy ... sclerosis (ALS). (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ... ascending,dose study in healthy volunteers is being ...
Other Medicine Technology:European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 2European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 3European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 4European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 5European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 6European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 7European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy 8Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 2Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: